Salix sets launch of $1.35 billion loan for Santarus buy
NEW YORK (Reuters) - Salix Pharmaceuticals Ltd (SLXP.O) is planning to launch next week $1.35 billion in senior secured debt financing to fund its $2.6 billion acquisition of biopharmaceutical company Santarus Inc SNTS.O, sources told Thomson Reuters LPC.
A bank meeting is set for 1:30 p.m. December 3.
Jefferies leads the transaction together with joint leads Fifth Third, PNC, SunTrust and Sumitomo Mitsui Banking Corp. Natixis and RBS Citizens are senior managing agents.
The debt package is split between a $150 million revolving credit and a $1.2 billion term loan, sources said.
Salix earlier indicated it also intends to finance the transaction with $800 million in cash.
Jefferies declined to comment.
Raleigh, N.C.-based Salix is acquiring Santarus for $32 per share, which represents a 36 percent premium over Santarus' November 6 closing price of $23.53 and a roughly 39 percent premium over Santarus' average closing price for the past 30-day trading period.
The transaction is expected to close in the first quarter of 2014.
(Editing By Jon Methven)
- Total CEO de Margerie killed in Moscow as jet hits snow plow |
- Pistorius starts five-year term for killing Reeva Steenkamp
- Ebola crisis turns a corner as U.S. issues new treatment protocols
- Fashion designer Oscar de la Renta dead at 82 |
- U.S. Congress examining deal between NSA official, ex-agency chief